Bryan J. McMichael - 07 Sep 2022 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Title: Senior Vice President, Accounting, Corporate Controller and Principal Accounting Officer
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Bryan J. McMichael
Issuer symbol
CHRS
Transactions as of
07 Sep 2022
Net transactions value
$0
Form type
4
Filing time
09 Sep 2022, 17:37:06 UTC
Next filing
06 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +15,000 $0.000000 15,000 07 Sep 2022 Common Stock 15,000 $10.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from September 7, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

Title: Senior Vice President, Accounting, Corporate Controller and Principal Accounting Officer